Miguel Angel Villalona Calero

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
ORCID ORCID Icon0000-0002-1991-5070 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Universidad Nacional Pedro Henriquez Urena, Santo Domingo, Dominican RepublicMD04/1985Medicine
    State University of New York Health Sciences Center at Brooklyn/Kings Co. Downstate Medical Center, Brooklyn NY06/1989Internal Medicine Residency
    University of Minnesota Hospital and Clinics, Minneapolis MN06/1990Medical Oncology Fellowship
    Roswell Park Cancer Institute, Buffalo, NY06/1992Medical Oncology Fellowship
    University of Texas Health Science Center at San Antonio, San Antonio, Texas07/1994Drug Development of Anticancer Agents
    New York University, Robert Wagner School of Public Health, NYC, NY06/2002Health Policy Leadership
    Collapse Awards and Honors
    Fundacion Oscar de la Renta2022  - 2022Finalist Premio Oscar de la Renta al Emigrante Dominicano
    Universidad Nacional Pedro Henriquez Urena2019  - 2019Honorary Professor, Universidad Nacional Pedro Henriquez Urena
    Universidad Autonoma de Santo Domingo2018  - 2018Honorary Professor, Universidad Autonoma de Santo Domingo
    Dominican society of Hematology and Oncology2018  - 2018Dedication of the Summer Congress of the Dominican Republic
    Florida International University2018  - 2018Top Scholar for Research and Creative Activities
    National Cancer Institute 2017  - 2017Continuing Umbrella of Research Experiences Lifetime Achievement Award
    American association for the Advancement of Science2013  - 2013Fellow
    National Cancer Institute2008  - 2008Outstanding Example of Translational Research
    V Foundation2005  - 2005V Foundation/American Association for Cancer Research Translational Cancer Research Award
    Alumni Association Universidad Autonoma de Santo Domingo, Inc., 2003  - 2003The Fray Anton de Montesinos Award to the Dominican Professional of the Year in The United States
    The Ohio State University2002  - 2002Tenure
    American College of Physicians/American Society of Internal Medicine1999  - 1999Fellow

    Collapse Overview 
    Collapse Overview
    Division Chief Hematology & Oncology
    University of California Irvine
    Deputy Director, Chao Family Comprehensive Cancer Center
    Orange, CA

    Dr. Villalona-Calero received his medical degree (magna cum laude) from Universidad Nacional Pedro Henríquez Ureña, Dominican Republic. He completed residency in internal medicine at State University of New York Health Science Center at Brooklyn. He subsequently completed fellowships in Medical Oncology at the University of Minnesota, and Roswell Park Cancer Institute, a fellowship in drug development at the University of Texas at San Antonio, and a Health Policy Leadership fellowship at New York University, Robert Wagner School of Public Service. Dr. Villalona was most recently Director of Experimental Therapeutics at City of Hope and Co-leader of the Developmental Therapeutics Program at the City of Hope Comprehensive Cancer Center. He was previously Deputy Director and Chief Scientific officer at Miami Cancer Institute, as well as tenured Professor and the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center.
    He is internationally recognized for his work in the areas of lung cancer and developmental therapeutics, designing new and more effective anticancer agents. Dr. Villalona is an inducted fellow from the American Association of the Advancement of Science and the American College of Physicians. His area of main expertise is in translating laboratory science to clinical trials in cancer patients. Over the last few years, he has been interested in genomic driven therapy, in ways of targeting deficiencies in DNA repair with agents that target alternative mechanisms of repair, and in novel ways to use the immune system to target cancer.

    Collapse Research 
    Collapse Research Activities and Funding
    Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
    NIH R01CA266457Aug 9, 2022 - Nov 30, 2027
    Role: Principal-Investigator
    The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
    NIH UM1CA186712Mar 28, 2014 - Feb 28, 2026
    Role: Principal-Investigator 2014-2015
    Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN
    NIH/NCI UM1CA186717Mar 28, 2014 - Feb 29, 2020
    Role: Principal-Investigator 2020-2024
    Training Hematology and Oncology Fellows in Clinical Research
    NIH T32CA165998Aug 1, 2012 - Jun 30, 2018
    Role: Principal-Investigator 2012-2015
    Targeting Somatic Homologous Recombination in Solid Tumors
    NIH R01CA152101Jul 1, 2010 - Dec 31, 2015
    Role: Principal-Investigator
    Biomodulation of capecitabine by docetaxel in non-small*
    NIH R21CA108157Apr 22, 2004 - Mar 31, 2007
    Role: Principal-Investigator
    TNF Blockade in Pancreatic Cancer Patients
    NIH R21CA101360Sep 30, 2003 - Aug 31, 2006
    Role: Principal-Investigator
    Phase II randomized trial of CPT-11 and Mitomycin C
    NIH R21CA092956Sep 24, 2002 - Aug 31, 2006
    Role: Principal-Investigator
    Suramin to Enchance Paclitaxel and Carboplatin in NSCLC
    NIH R21CA091547Sep 19, 2001 - Aug 31, 2005
    Role: Co-Principal Investigator (multi-PI)
    TRANSLATIONAL RESEARCH IN LUNG CANCER
    NIH K01CA076970Sep 30, 1997 - Sep 29, 2003
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. First-in-human trial of engineered NK cells in lung cancer refractory to immune checkpoint inhibitors. JCI Insight. 2025 Feb 04. Villalona-Calero MA, Tian L, Li X, Palmer JM, Aceves C, Meisen H, Cortez C, Synold TW, Egelston C, VanDeusen J, Bruno I, Zhang L, Romeu-Bonilla E, Butt O, Forman SJ, Caligiuri MA, Yu J. PMID: 39903538.
      View in: PubMed   Mentions:    Fields:    
    2. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica. 2025 Jan 01; 110(1):142-152. Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Siddiqi T, Danilov AV, Ruel N, Daniels S, Peters L, Khoo S, Rosen ST, Sharon E, Villalona-Calero M, Ruel C, Tuscano J, Herrera AF. PMID: 39021209; PMCID: PMC11694104.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    3. The Impact of Medicaid Expansion on Stage at Diagnosis of Melanoma Patients: A Retrospective Study. Cancers (Basel). 2024 Dec 28; 17(1). Muddasani R, Wu HT, Win S, Amini A, Modi B, Salgia R, Trisal V, Wang EW, Villalona-Calero MA, Chan A, Xing Y. PMID: 39796689; PMCID: PMC11719024.
      View in: PubMed   Mentions:
    4. Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2025 Feb; 210(1):179-189. Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B. PMID: 39644403.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    5. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024 Dec; 35(12):1138-1147. Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N, Ghiringhelli F, Goebeler ME, Doi T, Postel-Vinay S, Lin CC, Liu C, Chuang CH, Keyvanjah K, Eggert T, O'Neil BH. PMID: 39293516.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    6. Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer. Cancer Immunol Res. 2024 Jun 04; 12(6):731-743. Lu T, Ma R, Mansour AG, Bustillos C, Li Z, Li Z, Ma S, Teng KY, Chen H, Zhang J, Villalona-Calero MA, Caligiuri MA, Yu J. PMID: 38572955; PMCID: PMC11218741.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    7. A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report. Transl Lung Cancer Res. 2024 May 31; 13(5):1163-1168. Dias E Silva D, Mambetsariev I, Fricke J, Babikian R, Dingal ST, Mazdisnian F, Badie B, Arvanitis L, Afkhami M, Villalona-Calero M, Salgia R. PMID: 38854944; PMCID: PMC11157375.
      View in: PubMed   Mentions:
    8. A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 Nov 01; 30(11). Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH. PMID: 37702588; PMCID: PMC10585708.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    9. Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block. JCO Precis Oncol. 2023 Sep; 7:e2200445. Liu J, Amini A, Govindarajan A, Abuali T, Mambetsariev I, Massarelli E, Villaflor V, Villalona-Calero M, West H, Williams T, Salgia R. PMID: 37656950.
      View in: PubMed   Mentions: 3     Fields:    
    10. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2023 Nov; 24(7):651-659. Ebadi M, Ladbury C, Liu J, Rock A, Onyshchenko M, Villaflor V, Villalona-Calero M, Salgia R, Massarelli E, Lee P, Williams T, Amini A. PMID: 37714807.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience. J Clin Med. 2023 Jun 15; 12(12). Villalona-Calero MA, Malhotra J, Chung V, Xing Y, Gray SW, Hampel H, Gruber S, McDonnell K. PMID: 37373756; PMCID: PMC10299326.
      View in: PubMed   Mentions: 2  
    12. Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data. Contemp Clin Trials. 2023 Feb; 125:107083. Behrendt CE, Villalona-Calero MA, Newman EM, Frankel PH. PMID: 36638911.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022; 14:17588359221137429. Polintan ET, Canicula SK, Catahay JA, Lo KB, Villalona-Calero M, Loong HH. PMID: 36407786; PMCID: PMC9666866.
      View in: PubMed   Mentions:
    14. Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC. Cancers (Basel). 2022 Aug 18; 14(16). Novak J, Salgia R, West H, Villalona-Calero MA, Sampath S, Williams T, Villaflor V, Massarelli E, Pathak R, Koczywas M, Chau B, Amini A. PMID: 36010982; PMCID: PMC9406789.
      View in: PubMed   Mentions: 4  
    15. Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors. Biomark Res. 2022 Jun 03; 10(1):39. Villalona-Calero MA, Diaz JP, Duan W, Diaz Z, Schroeder ED, Aparo S, Gatcliffe T, Albrecht F, Venkatappa S, Guardiola V, Garrido S, Rubens M, DeZarraga F, Vuong H. PMID: 35658948; PMCID: PMC9164357.
      View in: PubMed   Mentions:
    16. Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States. JCO Oncol Pract. 2022 May; 18(5):367-369. Bosserman LD, Duma N, Villalona-Calero M, Lopes G, Cinar P. PMID: 35544649.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 Feb 01; 45(2):49-54. Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, Massarelli E, Salgia R, Pathak R, Villaflor V, Villalona-Calero M, Amini A. PMID: 34991107.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 01; 23(1):72-81. Page RD, Drusbosky LM, Dada H, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA, Leighl NB. PMID: 34782240.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    19. Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis. Cell Death Dis. 2021 Mar 17; 12(4):287. Voss OH, Arango D, Tossey JC, Villalona Calero MA, Doseff AI. PMID: 33731677; PMCID: PMC7969956.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    20. MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers. Sci Rep. 2021 Feb 24; 11(1):4420. Duan W, Tang S, Gao L, Dotts K, Fink A, Kalvala A, Aguila B, Wang QE, Villalona-Calero MA. PMID: 33627769; PMCID: PMC7904768.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    21. The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer. 2020 Aug 08; 20(1):738. Ramelow J, Brooks CD, Gao L, Almiman AA, Williams TM, Villalona-Calero MA, Duan W. PMID: 32770960; PMCID: PMC7414707.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    22. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. Oncologist. 2020 Aug; 25(8):e1158-e1169. Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B. PMID: 32452601; PMCID: PMC7418347.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    23. A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clin Cancer Res. 2020 Apr 15; 26(8):1796-1802. Paik PK, Kim RK, Ahn L, Plodkowski AJ, Ni A, Donoghue MTA, Jonsson P, Villalona-Calero M, Ng K, McFarland D, Fiore JJ, Iqbal A, Eng J, Kris MG, Rudin CM. PMID: 31919132; PMCID: PMC7169419.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    24. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019 Aug 01; 25(15):4691-4700. Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA. PMID: 30988079.
      View in: PubMed   Mentions: 245     Fields:    Translation:Humans
    25. Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice. Int J Cancer. 2019 Nov 01; 145(9):2418-2426. Duan W, Gao L, Kalvala A, Aguila B, Brooks C, Mo X, Ding H, Shilo K, Otterson GA, Villalona-Calero MA. PMID: 30873587.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    26. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Clin Lung Cancer. 2018 Nov; 19(6):e893-e900. Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, Shields PG, Carbone DP, Otterson GA. PMID: 30197259; PMCID: PMC7193681.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    27. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 Oct; 36(5):919-926. Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. PMID: 30083962; PMCID: PMC6153554.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    28. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018 May 09; 6(1):32. Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS. PMID: 29743104; PMCID: PMC5944039.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    29. EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors. Oncologist. 2018 Oct; 23(10):1127-1132. Vargas-Madueno F, Gould E, Valor R, Ngo N, Zhang L, Villalona-Calero MA. PMID: 29739898; PMCID: PMC6263129.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. NPJ Breast Cancer. 2016; 2:16037. Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. PMID: 28721390; PMCID: PMC5515340.
      View in: PubMed   Mentions: 21  
    31. Rad51C-ATXN7 fusion gene expression in colorectal tumors. Mol Cancer. 2016 Jun 13; 15(1):47. Kalvala A, Gao L, Aguila B, Dotts K, Rahman M, Nana-Sinkam SP, Zhou X, Wang QE, Amann J, Otterson GA, Villalona-Calero MA, Duan W. PMID: 27296891; PMCID: PMC4906819.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    32. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24(6):1150-1158. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. PMID: 27039845; PMCID: PMC4923331.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCellsCTClinical Trials
    33. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst. 2016 Jul; 108(7). Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. PMID: 26848151; PMCID: PMC4948564.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    34. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. PMID: 26846975; PMCID: PMC5075244.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    35. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2016 May 15; 22(10):2565-74. Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. PMID: 26719427; PMCID: PMC4867263.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCellsCTClinical Trials
    36. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer. 2016 Mar 15; 122(6):875-83. Villalona-Calero MA, Lam E, Otterson GA, Zhao W, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV. PMID: 26709987; PMCID: PMC5068485.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    37. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemother Pharmacol. 2015 Nov; 76(5):1005-12. Mikhail S, Lustberg MB, Ruppert AS, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. PMID: 26416564.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    38. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep. 2015 Jul 10; 5:12122. Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T. PMID: 26161813; PMCID: PMC4894406.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    39. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer. 2015 Nov; 16(6):466-74. Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA. PMID: 26123189; PMCID: PMC5076571.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    40. Overexpression of Rad51C splice variants in colorectal tumors. Oncotarget. 2015 Apr 20; 6(11):8777-87. Kalvala A, Gao L, Aguila B, Reese T, Otterson GA, Villalona-Calero MA, Duan W. PMID: 25669972; PMCID: PMC4496183.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    41. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1574-82. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. PMID: 25589624; PMCID: PMC4383665.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    42. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol. 2014; 4:368. Duan W, Gao L, Aguila B, Kalvala A, Otterson GA, Villalona-Calero MA. PMID: 25566506; PMCID: PMC4271581.
      View in: PubMed   Mentions: 23  
    43. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2015 Feb; 14(2):461-9. Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA. PMID: 25504632.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    44. Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations. Int J Environ Res Public Health. 2014 Sep 12; 11(9):9491-502. Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou X, Frankel W, Otterson GA, Beall HD, Zhao W. PMID: 25222473; PMCID: PMC4199031.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    45. Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. Int J Environ Res Public Health. 2014 Aug 25; 11(9):8645-60. Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou XP, Frankel W, Otterson GA, Zhao W. PMID: 25158139; PMCID: PMC4198984.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    46. From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience. Lung Cancer Manag. 2014 Aug 01; 4(3):315-324. Zhao W, Damodaran S, Villalona-Calero MA. PMID: 25580159; PMCID: PMC4286371.
      View in: PubMed   Mentions: 1  
    47. FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. Clin Cancer Res. 2014 Jul 15; 20(14):3884-95. Singh M, Leasure JM, Chronowski C, Geier B, Bondra K, Duan W, Hensley LA, Villalona-Calero M, Li N, Vergis AM, Kurmasheva RT, Shen C, Woods G, Sebastian N, Fabian D, Kaplon R, Hammond S, Palanichamy K, Chakravarti A, Houghton PJ. PMID: 24787670; PMCID: PMC4102646.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    48. Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. Clin Pharmacol Ther. 2014 Aug; 96(2):182-91. Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MA. PMID: 24781527; PMCID: PMC4180036.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    49. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014 Apr; 124(4):1582-6. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, Schiller J, Villalona-Calero MA, Meyerson M, Carbone DP. PMID: 24569458; PMCID: PMC3973082.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    50. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):214-21. Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA, Alliance for Clinical Trials in Oncology. PMID: 24419419; PMCID: PMC4284815.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    51. Y-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis. Hum Pathol. 2014 May; 45(5):1065-70. Chen W, Brodsky SV, Zhao W, Otterson GA, Villalona-Calero M, Satoskar AA, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T, Shilo K. PMID: 24746212; PMCID: PMC4271837.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    52. Race and ethnicity in cancer therapy: what have we learned? Clin Pharmacol Ther. 2014 Apr; 95(4):403-12. Grenade C, Phelps MA, Villalona-Calero MA. PMID: 24419564.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    53. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagn Pathol. 2013 Dec 10; 8:201. Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GA. PMID: 24326178; PMCID: PMC3933389.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    54. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013 Jul; 42(5):813-8. Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TS. PMID: 23429495; PMCID: PMC3664263.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    55. Case of sorafenib-induced thyroid storm. J Clin Oncol. 2013 Jun 01; 31(16):e262-4. Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SW. PMID: 23610115.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    56. Inhibition of Ras-Effector Interaction by Cyclic Peptides. Medchemcomm. 2013 Feb 01; 4(2):378-382. Wu X, Upadhyaya P, Villalona-Calero MA, Briesewitz R, Pei D. PMID: 23585920; PMCID: PMC3621770.
      View in: PubMed   Mentions: 28  
    57. In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. AAPS J. 2013 Jan; 15(1):242-9. Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G. PMID: 23180159; PMCID: PMC3535094.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    58. RET fusion genes in non-small-cell lung cancer. J Clin Oncol. 2012 Dec 10; 30(35):4439-41. Chao BH, Briesewitz R, Villalona-Calero MA. PMID: 23150705.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    59. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2013 Jan; 79(1):27-32. Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA. PMID: 23079156; PMCID: PMC3549571.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    60. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res. 2013 Mar; 161(3):156-64. Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MA. PMID: 23063585; PMCID: PMC3755957.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    61. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol. 2013 Jan; 71(1):115-21. Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GA. PMID: 23053268.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    62. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 2012 Jun 10; 30(17):2063-9. Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA. PMID: 22547605; PMCID: PMC3397694.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCTClinical Trials
    63. Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer. J Oncol. 2012; 2012:957437. Zhao W, Huang CC, Otterson GA, Leon ME, Tang Y, Shilo K, Villalona MA. PMID: 22619677; PMCID: PMC3350860.
      View in: PubMed   Mentions: 16  
    64. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012; 82(3):175-9. Peck J, Wei L, Zalupski M, O'Neil B, Villalona Calero M, Bekaii-Saab T. PMID: 22433475.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    65. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. PMID: 21716143; PMCID: PMC3220078.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    66. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Feb; 69(2):523-31. Lam ET, Goel S, Schaaf LJ, Cropp GF, Hannah AL, Zhou Y, McCracken B, Haley BI, Johnson RG, Mani S, Villalona-Calero MA. PMID: 21874318; PMCID: PMC3865603.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    67. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors. Invest New Drugs. 2012 Aug; 30(4):1676-83. Monk JP, Villalona-Calero M, Larkin J, Otterson G, Spriggs DS, Hannah AL, Cropp GF, Johnson RG, Hensley ML. PMID: 21826439; PMCID: PMC5098268.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    68. Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library. ACS Comb Sci. 2011 Sep 12; 13(5):486-95. Wu X, Wang L, Han Y, Regan N, Li PK, Villalona MA, Hu X, Briesewitz R, Pei D. PMID: 21766878; PMCID: PMC3171579.
      View in: PubMed   Mentions: 12     Fields:    Translation:Cells
    69. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia. 2011 Sep; 25(9):1444-51. Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. PMID: 21606960; PMCID: PMC3162125.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    70. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10; 29(17):2357-63. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. PMID: 21519026; PMCID: PMC3107751.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansCellsCTClinical Trials
    71. Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer. Ann Thorac Surg. 2011 Feb; 91(2):640. Bertino E, Villalona-Calero MA, Ross P, Grever M, Otterson GA. PMID: 21256341; PMCID: PMC4271821.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    72. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Dec; 51(12):2222-9. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N. PMID: 21054149; PMCID: PMC3928074.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    73. The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods. Methods. 2010 Dec; 52(4):281-6. Yan F, Wu X, Crawford M, Duan W, Wilding EE, Gao L, Nana-Sinkam SP, Villalona-Calero MA, Baiocchi RA, Otterson GA. PMID: 20888418; PMCID: PMC3375896.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    74. MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. Int J Cancer. 2010 Jul 15; 127(2):313-20. Duan W, Gao L, Wu X, Wang L, Nana-Sinkam SP, Otterson GA, Villalona-Calero MA. PMID: 19921694; PMCID: PMC4153870.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    75. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol. 2010 May; 5(5):713-8. Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. PMID: 20354452; PMCID: PMC3641556.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    76. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res. 2010 Apr 15; 16(8):2466-73. Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR. PMID: 20371682; PMCID: PMC4262532.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    77. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10; 28(14):2323-30. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. PMID: 20368568; PMCID: PMC2881718.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansCTClinical Trials
    78. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20; 107(16):7473-8. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. PMID: 20368434; PMCID: PMC2867720.
      View in: PubMed   Mentions: 208     Fields:    Translation:HumansCellsCTClinical Trials
    79. Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis. Am J Clin Oncol. 2010 Feb; 33(1):109. Hamadani M, Awan F, Villalona-Calero MA. PMID: 20139744.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    80. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1019-29. Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA. PMID: 20107799; PMCID: PMC2919610.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    81. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun. 2010 Jan 15; 391(3):1465-70. Kosuri KV, Wu X, Wang L, Villalona-Calero MA, Otterson GA. PMID: 20035722; PMCID: PMC2860267.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    82. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10; 27(35):6012-8. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. PMID: 19826119; PMCID: PMC2793044.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCellsCTClinical Trials
    83. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15; 15(18):5895-901. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. PMID: 19737952; PMCID: PMC2774354.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    84. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. Cancer Chemother Pharmacol. 2010 Apr; 65(5):863-9. Bekaii-Saab T, Hill M, Campbell A, Kosuri K, Thomas J, Villalona-Calero M. PMID: 19657639; PMCID: PMC4261191.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    85. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS One. 2009; 4(5):e5563. Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, Barsky SH, Otterson GA, Villalona-Calero MA. PMID: 19440353; PMCID: PMC2680060.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    86. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11):1800-5. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ. PMID: 19255312; PMCID: PMC2668705.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    87. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2009 Jan; 94(1):164-70. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH. PMID: 18854394; PMCID: PMC2630867.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    88. Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemother Pharmacol. 2009 May; 63(6):1073-82. Xu Y, Kolesar JM, Schaaf LJ, Drengler R, Duan W, Otterson G, Shapiro C, Kuhn J, Villalona-Calero MA. PMID: 18795290; PMCID: PMC3933356.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    89. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol. 2008 Nov; 19(11):1903-9. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL. PMID: 18632723; PMCID: PMC2733080.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    90. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol. 2008 Aug; 19(8):1417-1422. Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL. PMID: 18407955.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    91. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice. Transgenic Res. 2008 Jun; 17(3):355-66. Duan W, Gao L, Jin D, Otterson GA, Villalona-Calero MA. PMID: 17968669.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    92. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. PMID: 17634483.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    93. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007 Feb 15; 13(4):1246-52. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, Kraut M, Mani S, Murren JR. PMID: 17317836.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    94. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers Surg Med. 2006 Dec; 38(10):881-9. Ross P, Grecula J, Bekaii-Saab T, Villalona-Calero M, Otterson G, Magro C. PMID: 17115382.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    95. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp Cell Res. 2006 Oct 15; 312(17):3370-8. Duan W, Gao L, Wu X, Zhang Y, Otterson GA, Villalona-Calero MA. PMID: 16934800.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    96. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Breast Cancer. 2006 Jun; 7(2):141-5. Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, Moore T, Hauger M, Watson H, Merriman N, Nadella P, Villalona-Calero M, Shapiro CL. PMID: 16800973.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    97. Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. Pharm Res. 2006 Jun; 23(6):1265-74. Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever M, Murgo AJ, Au JL. PMID: 16715360.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    98. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. Cancer Chemother Pharmacol. 2007 Jan; 59(1):23-33. Villalona-Calero M, Schaaf L, Phillips G, Otterson G, Panico K, Duan W, Kleiber B, Shah M, Young D, Wu WH, Kuhn J. PMID: 16685529.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    99. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006 Apr 20; 24(12):1852-9. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. PMID: 16622259.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    100. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006 Feb 01; 24(4):552-62. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. PMID: 16391300.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    101. A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors. Invest New Drugs. 2005 Dec; 23(6):555-62. Otterson GA, Lavelle J, Villalona-Calero MA, Shah M, Wei X, Chan KK, Fischer B, Grever M. PMID: 16034523.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    102. Limitations of single-strand conformation polymorphism analysis as a high-throughput method for the detection of EGFR mutations in the clinical setting. J Clin Oncol. 2005 Aug 20; 23(24):5847-8; author reply 5848-9. Weber F, Fukino K, Villalona-Calero M, Eng C. PMID: 16110042.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    103. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer. 2005 May 23; 92(10):1922-6. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, Plass C, Caldes T, Mutter GL, Villalona-Calero MA, Eng C. PMID: 15841079; PMCID: PMC2361765.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    104. Preclinical experience with docetaxel in gastrointestinal cancers. Semin Oncol. 2005 Apr; 32(2 Suppl 4):S3-9. Bekaii-Saab TS, Villalona-Calero MA. PMID: 16015550.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    105. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 2005 Mar 01; 11(5):1870-6. Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R, Villalona-Calero MA. PMID: 15756012.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    106. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst. 2004 Nov 17; 96(22):1718-21. Duan W, Gao L, Druhan LJ, Zhu WG, Morrison C, Otterson GA, Villalona-Calero MA. PMID: 15547185.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    107. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6086-93. Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Geary R, Oliver JW, Holmlund J. PMID: 15447994.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    108. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2004 Jun; 15(6):915-20. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE, University of Chicago Phase II Network, Ohio State University. PMID: 15151948.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    109. 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004 Apr 09; 279(15):15161-6. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, Otterson GA. PMID: 14722112.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    110. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. PMID: 14630685.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    111. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2003 Aug 15; 9(9):3303-11. Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D, Murgo AJ, Fischer B, DeHoff C, Chen D, Yeh TK, Song S, Grever M, Au JL. PMID: 12960116.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    112. P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochem Biophys Res Commun. 2003 Jun 13; 305(4):950-6. Ding H, Duan W, Zhu WG, Ju R, Srinivasan K, Otterson GA, Villalona-Calero MA. PMID: 12767922.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    113. Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol. 2003 Jun; 23(12):4056-65. Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA. PMID: 12773551; PMCID: PMC156121.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCells
    114. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002 Dec; 13(12):1841-51. Xu Y, Villalona-Calero MA. PMID: 12453851.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansAnimals
    115. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene. 2002 Nov 07; 21(51):7831-8. Duan W, Ding H, Subler MA, Zhu WG, Zhang H, Stoner GD, Windle JJ, Otterson GA, Villalona-Calero MA. PMID: 12420220.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    116. Mitomycin as a modulator of irinotecan anticancer activity. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):21-5. Villalona-Calero MA, Kolesar JM. PMID: 12199629.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    117. RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. Biotechniques. 2002 Jul; 33(1):58, 60-2, 64 passim. Duan W, Ding H, Zhu WG, Srinivasan K, Otterson GA, Villalona-Calero MA, Ottersom GA. PMID: 12139258.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    118. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res. 2002 Jul; 8(7):2142-8. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG. PMID: 12114414.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    119. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol. 2002 Jun 01; 20(11):2616-23. Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, Clinton S, Shah M, Stanek M, Monk P, Villalona-Calero MA. PMID: 12039922.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    120. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 2002 Apr; 13(4):539-45. Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. PMID: 12056703.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    121. Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer. 2002 Jan; 2(4):287-93. Maher JF, Villalona-Calero MA. PMID: 11899360.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    122. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002 Jan; 8(1):75-85. Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK. PMID: 11801542.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    123. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene. 2001 Nov 22; 20(53):7787-96. Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, Otterson GA. PMID: 11753657.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    124. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol. 2001 Nov; 12(11):1631-41. Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD. PMID: 11822765.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    125. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol. 2001 May; 12(5):605-14. Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK. PMID: 11432617.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    126. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. J Clin Oncol. 2001 Feb 01; 19(3):857-69. Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK. PMID: 11157040.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    127. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol. 2000 Dec 15; 18(24):4086-97. Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. PMID: 11118470.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    128. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol. 2000 Jan; 18(1):167-77. Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK. PMID: 10623707.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    129. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. Clin Cancer Res. 1999 Nov; 5(11):3369-78. Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, Drengler R, Simmons C, Santabarbara P, Von Hoff DD, Rowinsky EK. PMID: 10589747.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    130. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res. 1999 Jul; 5(7):1629-37. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG. PMID: 10430061.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    131. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol. 1999 Jun; 17(6):1915-25. Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK. PMID: 10561233.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    132. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol. 1999 Apr; 17(4):1095-104. Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG, Villalona-Calero MA, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckardt JR, Moczygemba J, Hannah AL, Von Hoff DD, Rowinsky EK. PMID: 10561166.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    133. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol. 1999 Feb; 17(2):685-96. Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML. PMID: 10080615.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    134. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. Clin Cancer Res. 1999 Feb; 5(2):299-308. Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK. PMID: 10037178.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    135. New anticancer agents. Cancer Chemother Biol Response Modif. 1999; 18:178-209. Britten C, Hammond L, Hidalgo M, Rothenberg ML, Sharma A, Sharma S, Siu L, Villalona-Calero M, Weiss GR. PMID: 10800483.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    136. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998 Sep; 16(9):2964-76. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J, Harding MW, Von Hoff DD. PMID: 9738565.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    137. Alternative dosing schedules for irinotecan. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):68-71. Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD. PMID: 9726095.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    138. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J Clin Oncol. 1998 Aug; 16(8):2770-9. Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. PMID: 9704730.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    139. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol. 1998 Jul; 9(7):733-8. Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris HA, Eckhardt SG, Stephens CD, Forral K, Nicol SJ, Von Hoff DD. PMID: 9739439.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    140. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol. 1998 Jan; 9(1):71-7. Villalona-Calero MA, Eckardt J, Burris H, Kraynak M, Fields-Jones S, Bazan C, Lancaster J, Hander T, Goldblum R, Hammond L, Bari A, Drengler R, Rothenberg M, Hadovsky G, Von Hoff DD. PMID: 9541686.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    141. New anticancer agents in clinical development. Oncology (Williston Park). 1995 Dec; 9(12):1321-8; 1331; discussion 1332-4. Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. PMID: 8771106.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    142. New anticancer agents in clinical development. Oncology (Williston Park). 1995 Nov; 9(11):1191-9. Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. PMID: 8703688.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    143. Secondary acute myelogenous leukemia in children with Latin-American ancestry. J Clin Oncol. 1993 Nov; 11(11):2286. Villalona-Calero MA. PMID: 8229144.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    144. Acute progranulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF). Leukemia. 1993 Oct; 7(10):1680-1. Vaickus L, Villalona-Calero MA, Caligiuri T. PMID: 7692195.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    145. Pretraining for international medical graduates. Ann Intern Med. 1993 Mar 01; 118(5):397-8. Villalona-Calero M. PMID: 8430994.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    146. Extragonadal abdominal germ cell cancers. Am J Clin Oncol. 1992 Aug; 15(4):308-10. Gonzalez-Vela JL, Villalona-Calero MA, Torkelson JL, Fraley EE, Kennedy BJ. PMID: 1381144.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    147. Management of testicular seminoma following organ transplantation. Med Pediatr Oncol. 1992; 20(4):338-40. Villalona-Calero MA, Ducker T, Holasek M, Najarian J, Kennedy BJ. PMID: 1608358.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    148. Pneumomediastinum complicating Pneumocystis carinii pneumonia in a patient with AIDS. Am J Med Sci. 1989 May; 297(5):328-30. Villalona-Calero MA, Schrem SS, Phelps KR. PMID: 2785760.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Miguel's Networks
    Concepts (587)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California